BeOne Medicines Ltd. - Sponsored ADR (ONC) Business Profile

What it does

BeOne Medicines discovers, develops and sells medicines for cancer. Founded in 2010, it is a Swiss-incorporated holding company whose operations are conducted mainly through subsidiaries in the United States, China, the United Kingdom and Australia. John Oyler is its co-founder, chairman and chief executive. The company had 12,000 employees in FY2025.

Its blood cancer business is led by BRUKINSA, an oral medicine that blocks a protein called BTK. It is approved for several B-cell cancers, including chronic lymphocytic leukemia and mantle cell lymphoma. The company also sells TEVIMBRA, an antibody designed to act on the PD-1 immune checkpoint, for certain solid tumors. Its approved uses vary by country and include some lung, esophageal and gastric cancers.

BeOne develops additional medicines for blood cancers, including sonrotoclax, a BCL2 inhibitor approved in China, and tacabrutideg, a BTK-targeted protein degrader in clinical development. Its solid tumor pipeline includes antibody-based therapies and small-molecule drugs for cancers such as breast, lung, liver and gastrointestinal tumors.

Alongside its own medicines, BeOne commercializes medicines licensed from other companies. For example, it sells Amgen’s XGEVA, BLINCYTO and KYPROLIS in China. Its medicines reach patients through commercial operations in markets including the United States, Europe and China, with reimbursement from government programs and private payers playing a role in access.

How it makes money

BeOne earns most of its revenue by selling cancer medicines. It has global commercial rights to its internally developed BRUKINSA and TEVIMBRA, as well as to sonrotoclax and PARTRUVIX. It also earns revenue from products licensed for particular territories and from other arrangements, including royalties and promotion agreements.

Total revenue was $5.3 billion in FY2025 and $1.9 billion in Q3 2026.

Net product revenue was $5.3 billion in FY2025, representing 98.9% of revenue. BRUKINSA generated $3.9 billion in global sales that year, while TEVIMBRA generated $737.3 million. Other revenue was $61.0 million, primarily from royalties under the Amgen collaboration and a marketing and promotion agreement with Novartis.

Patients may receive medicines as ongoing treatment or for a fixed duration, depending on the regimen. BeOne is studying BRUKINSA both on its own and in combinations, including with sonrotoclax. Product sales depend on physician prescribing, patient use and reimbursement rather than a subscription contract.

Prices and reimbursement arrangements differ by market. In the United States, private insurers and public programs cover pharmaceutical products, and prices paid can vary. In China, inclusion of newer medicines on the national reimbursement list typically follows negotiation and a discount to the prevailing list price. BeOne offers U.S. patient assistance that can include reimbursement support, co-pay assistance and free product for eligible patients.

In Q3 2026, BRUKINSA generated approximately $1.4 billion in global revenue. BeOne said U.S. BRUKINSA sales benefited from approximately $50 million of order timing, including an extra shipping day. The company also said BEQALZI had launched in the United States for relapsed or refractory mantle cell lymphoma.

Customers and how it sells

BeOne’s medicines are prescribed for cancer patients, while access and payment depend on physicians, health systems and third-party payers. In the United States, payers include private insurers and the Medicare and Medicaid programs. In China, the government’s national health care coverage system is the main payer, and national reimbursement decisions affect access to medicines.

Revenue is also concentrated among named customers. In FY2025, ASD Specialty Healthcare accounted for 18.5% of revenue, McKesson for 17.5% and Shanghai Pharmaceutical for 10.1%.

The United States generated $2.9 billion of FY2025 revenue, or 53.9% of the total. China generated $1.7 billion, or 31.4%, and Europe generated $611.4 million, or 11.4%. BeOne had commercialized products in over 60 markets as of December 31, 2025.

The company has its own commercial capabilities in the United States, the European Union and China and has been expanding into Asia Pacific, Latin America and the Middle East. It also uses co-promotion and contract sales arrangements where its direct sales force is not sufficiently large or aligned. In Q3 2026, the company reported contributions from markets including Japan and Brazil, alongside sales in its larger regions.

Suppliers and costs

BeOne has clinical development and manufacturing operations of its own, but relies on third parties to manufacture some commercial and clinical drug supplies. It says the number of potential manufacturers is limited and that regulators must evaluate or approve manufacturers as part of their oversight. Raw materials and components, including some for which BeOne has no alternative source, may be unavailable or unsuitable for use.

The company has built a global clinical team that allows it to run trials largely without relying on contract research organizations. Its commercial portfolio also includes medicines licensed from partners, including Amgen. Such collaborations can involve development obligations as well as rights to sell products.

Research and development expense was $2.1 billion in FY2025. Gross margin on product sales was 87.3% in the same year. BeOne attributed the increase in gross margin to a higher proportion of BRUKINSA sales and production productivity improvements for BRUKINSA and TEVIMBRA, partly offset by manufacturing-capacity repositioning costs.

In Q3 2026, operating expenses were approximately $1.25 billion. BeOne expects operating expenses to grow in 2027 at least in line with their growth over the preceding several years as it invests in its pipeline.

Competitive position

BeOne competes on efficacy, safety and cost, and must demonstrate the value of its medicines to physicians, patients and payers. BRUKINSA competes with AbbVie and Janssen’s IMBRUVICA, AstraZeneca’s CALQUENCE and Eli Lilly’s JAYPIRCA across major markets. In China and Singapore it also competes with Innocare’s YINUOKAI.

TEVIMBRA competes with medicines including Merck’s KEYTRUDA, Bristol Myers Squibb’s OPDIVO and AstraZeneca’s IMFINZI. Sonrotoclax faces AbbVie and Roche’s VENCLEXTA and Ascentage Pharma’s Lisaftoclax in China. In the pipeline, Nurix Therapeutics is developing a BTK degrader that competes with BeOne’s BGB-16673.

BRUKINSA is approved in 77 markets and reimbursed in 58 markets. In a head-to-head trial, it demonstrated progression-free survival superiority over ibrutinib in relapsed or refractory chronic lymphocytic leukemia. BeOne also has a global clinical team and commercial operations in major markets.

Our reading: BRUKINSA’s trial evidence and market reach provide a meaningful commercial advantage, although competing BTK inhibitors remain available. Our reading: The in-house clinical network and established sales presence support development and distribution, but their durability depends on continued investment and successful execution against larger competitors.

Growth opportunities

BeOne is seeking to expand sales of BRUKINSA through additional indications and combinations. The company said it had submitted BRUKINSA for previously untreated mantle cell lymphoma in the United States, Europe and China, and that the U.S. application had received priority review. It is also studying BRUKINSA with sonrotoclax in previously untreated chronic lymphocytic leukemia.

Sonrotoclax has been approved in China, and BeOne said BEQALZI had launched in the United States for relapsed or refractory mantle cell lymphoma. The company is developing tacabrutideg for patients whose disease has returned or stopped responding to treatment. BeOne said its Phase 2 trial met its primary response-rate endpoint, while the FDA requested additional follow-up for a potential accelerated approval submission.

In solid tumors, BeOne is developing treatments for breast, lung, liver and gastrointestinal cancers. It is increasing the size of the Phase 3 KANDELA-302 study of its CDK4 inhibitor and has enrolled the first subject in a Phase 3 study of its B7-H4 antibody-drug conjugate. The company also launched a TEVIMBRA-containing regimen in the United States after approval for first-line HER2-positive gastroesophageal adenocarcinoma.

For context, BeOne estimated the global chronic lymphocytic leukemia market at approximately $12 billion. The company raised its 2026 revenue guidance.

Structural risks

• Product concentration and acceptance. BRUKINSA generated $3.9 billion of BeOne’s FY2025 sales. Its medicines may fail to achieve or maintain the acceptance among physicians, patients and payers needed for commercial success, and sales depend on coverage and reimbursement.
• Clinical and regulatory outcomes. Candidates can be delayed or denied approval if trials do not establish the required safety and efficacy, results fail to meet statistical requirements, or regulators request further data. BeOne said the FDA requested additional follow-up for a potential tacabrutideg submission.
• Competition and pricing. Competing medicines vie on efficacy, safety and cost. BeOne said it was beginning to see an impact from XGEVA biosimilars and expects that competition and potential procurement-list inclusion could pressure XGEVA and KYPROLIS revenue beyond 2026.
• Manufacturing and supply. BeOne relies on a limited number of third-party manufacturers for some supplies. Manufacturers may be unable to produce medicines on time or in the required quantity or quality, while raw materials and components may be disrupted.
• Intellectual property and financial results. Failure to obtain or maintain patent protection could result in lost market exclusivity. BeOne has historically incurred significant net losses and may incur losses again.

Bottom line

Our reading

BeOne is a commercial oncology company whose sales and cash generation are anchored by BRUKINSA, while TEVIMBRA, licensed products and a developing pipeline provide additional sources of business. Its global clinical and commercial infrastructure supports expansion, but future results remain exposed to competition, reimbursement, manufacturing and the uncertain outcomes of clinical trials and regulatory reviews. Continued pipeline spending is part of the model, not separate from it.